
Tremelimumab
CAS No. 745013-59-6
Tremelimumab( —— )
Catalog No. M36905 CAS No. 745013-59-6
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 236 | Get Quote |
![]() ![]() |
5MG | 448 | Get Quote |
![]() ![]() |
10MG | 656 | Get Quote |
![]() ![]() |
25MG | 994 | Get Quote |
![]() ![]() |
50MG | 1343 | Get Quote |
![]() ![]() |
100MG | 1773 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTremelimumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionTremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
-
DescriptionTremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
-
In VitroTremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans.Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner.Tremelimumab enhances the IL-2 production in T-cells.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number745013-59-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76.?
molnova catalog



related products
-
Mesaconitine
Mesaconitine has antinociceptive activity through cyclic AMP and stimulation of the central β-adrenergic system.
-
Panaxydiol
Panaxydiol is a natural product for research related to life sciences.
-
Ilexoside XLVIII
Ilexoside XLVIII is an acyl CoA cholesteryl acyl transferase ( ACAT ) inhibitor. Ilexoside XLVIII is a triterpene saponin isolated from an aqueous extract of the leaves of Ilex kudincha.